Disclosures for "African-American MS Patients with and Without Early B-cell Repletion After Anti-CD20 Monoclonal Infusion Therapy Have Similarly Low Levels of Disease Activity"
-
Dr. Kopinsky has nothing to disclose.
-
Ms. Kim has nothing to disclose.
-
Dr. Amarnani has nothing to disclose.
-
Dr. Arbini has nothing to disclose.
-
Dr. Fenyo has nothing to disclose.
-
Author has nothing to disclose
-
Dr. Kister has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech-Roche. Dr. Kister has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. The institution of Dr. Kister has received research support from Genentech. The institution of Dr. Kister has received research support from Novartis. Dr. Kister has received publishing royalties from a publication relating to health care.